Sign in

    Craig Suvanevej

    Managing Director and Senior Biopharmaceuticals and Biotechnology Equity Research Analyst at Mizuho Securities USA LLC

    Graig C. Suvannavejh is a Managing Director and Senior Biopharmaceuticals and Biotechnology Equity Research Analyst at Mizuho Securities USA LLC, with over 20 years of experience in healthcare research and industry. He covers leading biotechnology and pharmaceutical companies including Alector, Amylyx Pharmaceuticals, Axsome Therapeutics, Athira Pharma, BioXcel Therapeutics, Cerevel Therapeutics, Harmony Biosciences, Immatics, Immunocore, Insmed, Intra-Cellular Therapies, Karuna Therapeutics, Rain Oncology, Vigil Neuroscience, Selecta Biosciences, and uniQure, providing high-impact investment analysis built on extensive sector expertise. Suvannavejh joined Mizuho in January 2022 from Goldman Sachs, where he established and led the European biotechnology research franchise and contributed to US biopharmaceutical coverage, following roles at AbbVie and Biogen in business development and strategy. He holds a B.S. in Biology and an M.S. in Physiology & Biophysics from Georgetown University, a Ph.D. in Neuroscience from Northwestern University, and brings strong sell-side and operational credentials to his role.

    Craig Suvanevej's questions to Corvus Pharmaceuticals (CRVS) leadership

    Craig Suvanevej's questions to Corvus Pharmaceuticals (CRVS) leadership • Q2 2025

    Question

    Sam, on behalf of Craig Suvanevej from Mizuho Securities, asked for an update on the enrollment progress for the socolitinib trial in Peripheral T-cell Lymphoma (PTCL) and sought confirmation on the previously guided timeline for interim data.

    Answer

    CEO Richard Miller confirmed that the PTCL trial enrollment is proceeding as planned, with approximately 20 centers now active in the U.S. and Canada. He reiterated that the company's guidance for releasing interim data in late 2026 remains intact.

    Ask Fintool Equity Research AI